Myostatin in idiopathic inflammatory myopathies: Serum assessment and disease activity
Open Access
- 7 October 2022
- journal article
- research article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 49 (1)
Abstract
Aims: In idiopathic inflammatory myopathies (IIM), disease activity is difficult to assess, and IIM may induce severe muscle damage, especially in immune‐mediated necrotising myopathies (IMNM) and inclusion body myositis (IBM). We hypothesise that myostatin, a negative regulator of muscle mass, could be a new biomarker of disease activity and/or muscle damage.Methods: Prospective assessment of myostatin protein level in 447 IIM serum samples (dermatomyositis [DM], n = 157; IBM, n = 72; IMNM, n = 125; and antisynthetase syndrome [ASyS], n = 93) and 59 healthy donors (HD) was performed by ELISA. A gene transcript analysis was also carried out on 18 IIM muscle biopsies and six controls to analyse myostatin and myostatin pathway‐related gene expression.Results: IIM patients had lower myostatin circulating protein levels and gene expression compared to HD (2379 [1490; 3678] pg/ml vs 4281 [3169; 5787] pg/ml; p < 0.0001 and log2FC = −1.83; p = 0.0005, respectively). Myostatin‐related gene expression varied accordingly. Based on the Physician Global Assessment, inactive IIM patients showed higher myostatin levels than active ones. This was the case for all IIM subgroups, except IMNM where low myostatin levels were maintained (2186 [1235; 3815] vs 2349 [1518; 3922] pg/ml; p = 0.4).Conclusions: Myostatin protein and RNA levels are decreased in all IIM patients, and protein levels correlate with disease activity. Inactive ASyS and DM patients have higher myostatin levels than active patients. Myostatin could be a marker of disease activity in these subgroups. However, IMNM patients do not have significant increase in myostatin levels after disease remission. This may highlight a new pathological disease mechanism in IMNM patients.Keywords
This publication has 38 references indexed in Scilit:
- Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross‐sectional study and review of literatureJournal of Cachexia, Sarcopenia and Muscle, 2012
- Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteinsAmerican Journal of Physiology-Cell Physiology, 2011
- Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C‐HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF‐36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index‐2 (FI‐2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)Arthritis Care & Research, 2011
- The Regulation and Functions of Activin and Follistatin in Inflammation and Immunity2011
- Influence of Muscle Mass and Physical Activity on Serum and Urinary Creatinine and Serum Cystatin CClinical Journal of the American Society of Nephrology, 2008
- Myostatin is increased and complexes with amyloid-β within sporadic inclusion-body myositis muscle fibersActa Neuropathologica, 2005
- Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesisDevelopmental Biology, 2004
- Regulation of myostatin activity and muscle growthProceedings of the National Academy of Sciences, 2001
- Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies1This paper was presented at the 50th Annual Meeting of the American Academy of Neurology, Minneapolis, MN, USA, April 1998.1Neuromuscular Disorders, 1999
- Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathiesArthritis & Rheumatism, 1997